Hifuture Technology(SZ:002168)2025-09-25 10:26Financial Performance - The company repaid all acquisition loans to AVIC Trust amounting to 830 million yuan using self-owned and self-raised funds [1] - For the first half of 2025, the company achieved a total revenue of 179.79 million yuan [2] - The company aims to ensure the completion of its annual operational goals and mitigate delisting risks [3] Employee Information - As of December 31, 2024, the total number of employees is 383, excluding the subsidiary Ruien Pharmaceutical [2] Restructuring Plans - The company is currently in the pre-restructuring phase, with the Chongqing Fifth Intermediate People's Court completing the filing for pre-restructuring [3] - There is significant uncertainty regarding whether the company will formally enter the restructuring process [3] - The company signed restructuring investment agreements with strategic investors in September 2025, which may lead to changes in control [3][4] Debt and Compensation - The company is actively pursuing the collection of performance compensation from individuals, with a total of 135 million yuan already paid by Kou Han and 21.41 million yuan by Lin Jiaxi, leaving outstanding balances of 311.99 million yuan and 22.70 million yuan respectively [5][6] - The company is conducting a debt review as part of the pre-restructuring process, with specific figures to be disclosed in future announcements [5] Future Outlook - The company is focused on improving its core business operations and exploring partnerships to enhance market demand [8] - The introduction of strategic investors is expected to provide financial and operational support to improve the company's performance [9][10] - The company plans to implement a capital increase through the conversion of capital reserves, with a proposed ratio of 10 shares for every 4.8 shares issued [13][14]